首页> 美国卫生研究院文献>Malaria Journal >Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and Adenovirus (Ad5) immune mice
【2h】

Immunogenicity when utilizing adenovirus serotype 4 and 5 vaccines expressing circumsporozoite protein in naïve and Adenovirus (Ad5) immune mice

机译:在幼稚和腺病毒(Ad5)免疫小鼠中使用表达环孢子蛋白的腺病毒血清型4和5疫苗时的免疫原性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundInduction of potent long lasting effector T cell responses against liver stage malaria antigens strongly correlates with protection from malaria. While Adenovirus serotype 5 (Ad5) based malaria vaccine platforms have the ability to induce potent effector T cell responses against transgenes, high rates of pre-existing Ad5 immunity in malaria endemic regions has prompted study of alternative Ad serotype based malaria vaccines as replacements for Ad5 based malaria vaccines. The research described in this article examines the utility of alternative serotype adenovirus serotype 4 (Ad4) expressing a sporozoite surface protein (circumsporozoite protein (CSP)) (Ad4-CSP) to induce immune responses against CSP. The immunogenicity of Ad4-CSP was also tested in homologous and heterologous prime boost vaccinations in both Ad5 naïve and Ad5 immune backgrounds as compared to use of Ad5-CSP.
机译:背景诱导针对肝阶段疟疾抗原的有效的长效效应T细胞应答的诱导与对疟疾的防护密切相关。虽然基于腺病毒血清型5(Ad5)的疟疾疫苗平台具有诱导针对转基因的强效效应T细胞反应的能力,但疟疾流行地区预先存在的Ad5免疫率很高,这促使人们开始研究替代性的基于Ad血清型疟疾疫苗作为Ad5的替代品疟疾疫苗。本文中描述的研究检查了表达亚孢子表面蛋白(环子孢子蛋白(CSP))(Ad4-CSP)的替代血清型腺病毒4型(Ad4)诱导针对CSP的免疫反应的效用。与使用Ad5-CSP相比,还在Ad5原始和Ad5免疫背景下的同源和异源初免疫苗中测试了Ad4-CSP的免疫原性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号